AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (786.1 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

HOXB13 mutations and binding partners in prostate development and cancer: Function, clinical significance, and future directions

Hannah Brechkaa, Raj R. Bhanvadiab, Calvin VanOpstalla, Donald J. Vander Grienda,c( )
The Committee on Cancer Biology, The University of Chicago, Chicago, IL, USA
The Pritzker School of Medicine, The University of Chicago, Chicago, IL, USA
Department of Surgery, Section of Urology, The University of Chicago, Chicago, IL, USA

Peer review under responsibility of Chongqing Medical University.

Show Author Information

Abstract

The recent and exciting discovery of germline HOXB13 mutations in familial prostate cancer has brought HOX signaling to the forefront of prostate cancer research. An enhanced understanding of HOX signaling, and the co-factors regulating HOX protein specificity and transcriptional regulation, has the high potential to elucidate novel approaches to prevent, diagnose, stage, and treat prostate cancer. Toward our understanding of HOX biology in prostate development and prostate cancer, basic research in developmental model systems as well as other tumor sites provides a mechanistic framework to inform future studies in prostate biology. Here we describe our current understanding of HOX signaling in genitourinary development and cancer, current clinical data of HOXB13 mutations in multiple cancers including prostate cancer, and the role of HOX protein co-factors in development and cancer. These data highlight numerous gaps in our understanding of HOX function in the prostate, and present numerous potentially impactful mechanistic and clinical opportunities for future investigation.

Keywords

Androgen receptorHOXB13HOXB13(G84E)MEIS1MEIS2PBXProstateTALE

References

1

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66:7–30.
Crossref Google Scholar
2

Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366:141–149.
Crossref Google Scholar
3

Cerda-Esteban N, Spagnoli FM. Glimpse into Hox and tale regulation of cell differentiation and reprogramming. Dev Dyn. 2014;243:76–87.
Crossref Google Scholar
4

Huang L, Pu Y, Hepps D, Danielpour D, Prins GS. Posterior Hox gene expression and differential androgen regulation in the developing and adult rat prostate lobes. Endocrinology. 2007;148:1235–1245.
Crossref Google Scholar
5

Hamid SM, Cicek S, Karamil S, et al. HOXB13 contributes to G1/S and G2/M checkpoint controls in prostate. Mol Cell Endocrinol. 2014;383:38–47.
Crossref Google Scholar
6

Rezsohazy R, Saurin AJ, Maurel-Zaffran C, Graba Y. Cellular and molecular insights into Hox protein action. Development. 2015;142:1212–1227.
Crossref Google Scholar
7

Lappin TR, Grier DG, Thompson A, Halliday HL. HOX genes: seductive science, mysterious mechanisms. Ulst Med J. 2006;75:23–31.
Google Scholar
8

Prins GS, Putz O. Molecular signaling pathways that regulate prostate gland development. Differentiation. 2008;76:641–659.
Crossref Google Scholar
9

Takahashi Y, Hamada J, Murakawa K, et al. Expression profiles of 39 HOX genes in normal human adult organs and anaplastic thyroid cancer cell lines by quantitative real-time RT-PCR system. Exp Cell Res. 2004;293:144–153.
Crossref Google Scholar
10

Favier B, Dolle P. Developmental functions of mammalian Hox genes. Mol Hum Reprod. 1997;3:115–131.
Crossref Google Scholar
11

Mallo M, Wellik DM, Deschamps J. Hox genes and regional patterning of the vertebrate body plan. Dev Biol. 2010;344:7–15.
Crossref Google Scholar
12

Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer. 2002;2:777–785.
Crossref Google Scholar
13
Sadler TW. Urogenital system. In: Sadler TW, ed. Langman’s Medical Embryology. 12th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2012:232–259.
14
Rao M, Wilkinson MF. Homeobox genes and the male reproductive system. In: Robaire BaH BT, ed. The Epididymis: From Molecules to Clinical Practice. United States: Springer; 2002: 269–283.
Crossref
15

Warot X, Fromental-Ramain C, Fraulob V, Chambon P, Dolle P. Gene dosage-dependent effects of the Hoxa-13 and Hoxd-13 mutations on morphogenesis of the terminal parts of the digestive and urogenital tracts. Development. 1997;124:4781–4791.
Crossref Google Scholar
16

Podlasek CA, Duboule D, Bushman W. Male accessory sex organ morphogenesis is altered by loss of function of Hoxd-13. Dev Dyn. 1997;208:454–465.
Crossref Google Scholar
17

Economides KD, Capecchi MR. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development. 2003;130:2061–2069.
Crossref Google Scholar
18
Rao M, Wilkinson MF. Homeobox genes and the male reproductive system. In: Robaire B, Hinton BT, eds. The Epididymis: From Molecules to Clinical Practice: A Comprehensive Survey of the Efferent Ducts, the Epididymis and the Vas Deferens. Boston, MA: Springer US; 2002:269–283.
Crossref
19

Podlasek CA, Seo RM, Clemens JQ, Ma L, Maas RL, Bushman W. Hoxa-10 deficient male mice exhibit abnormal development of the accessory sex organs. Dev Dyn. 1999;214:1–12.
Crossref Google Scholar
20

Podlasek CA, Clemens JQ, Bushman W. Hoxa-13 gene mutation results in abnormal seminal vesicle and prostate development. J Urol. 1999;161:1655–1661.
Crossref Google Scholar
21

Xu J, Lange EM, Lu L, et al. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet. 2013;132:5–14.
Crossref Google Scholar
22

Akbari MR, Trachtenberg J, Lee J, et al. Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst. 2012;104:1260–1262.
Crossref Google Scholar
23

Gudmundsson J, Sulem P, Gudbjartsson DF, et al. A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nat Genet. 2012;44:1326–1329.
Crossref Google Scholar
24

Karlsson R, Aly M, Clements M, et al. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol. 2014;65:169–176.
Crossref Google Scholar
25

Kluzniak W, Wokolorczyk D, Kashyap A, et al. The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. Prostate. 2013;73:542–548.
Crossref Google Scholar
26

Kote-Jarai Z, Mikropoulos C, Leongamornlert DA, et al. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Ann Oncol. 2015;26:756–761.
Crossref Google Scholar
27

Laitinen VH, Wahlfors T, Saaristo L, et al. HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2013;22:452–460.
Crossref Google Scholar
28

Stott-Miller M, Karyadi DM, Smith T, et al. HOXB13 mutations in a population-based, case-control study of prostate cancer. Prostate. 2013;73:634–641.
Crossref Google Scholar
29

Storebjerg TM, Hoyer S, Kirkegaard P, et al. Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness. BJU Int. 2016;118:646–653.
Crossref Google Scholar
30

Kumar A, Coleman I, Morrissey C, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016;22:369–378.
Crossref Google Scholar
31

Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239–243.
Crossref Google Scholar
32

Cancer Genome Atlas Research N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011–1025.
Crossref Google Scholar
33

Lin X, Qu L, Chen Z, et al. A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate. 2013;73:169–175.
Crossref Google Scholar
34

Maia S, Cardoso M, Pinto P, et al. Identification of two novel HOXB13 germline mutations in Portuguese prostate cancer patients. PLoS One. 2015;10:e0132728.
Crossref Google Scholar
35

McMullin RP, Mutton LN, Bieberich CJ. Hoxb13 regulatory elements mediate transgene expression during prostate organogenesis and carcinogenesis. Dev Dyn. 2009;238:664–672.
Crossref Google Scholar
36

Sreenath T, Orosz A, Fujita K, Bieberich CJ. Androgen-independent expression of hoxb-13 in the mouse prostate. Prostate. 1999;41:203–207.
Crossref Google Scholar
37

Norris JD, Chang CY, Wittmann BM, et al. The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell. 2009;36:405–416.
Crossref Google Scholar
38

Akbari MR, Anderson LN, Buchanan DD, et al. Germline HOXB13 p.Gly84Glu mutation and risk of colorectal cancer. Cancer Epidemiol. 2013;37:424–427.
Crossref Google Scholar
39

Beebe-Dimmer JL, Hathcock M, Yee C, et al. The HOXB13 G84E mutation is associated with an increased risk for prostate cancer and other malignancies. Cancer Epidemiol Biomarkers Prev. 2015;24:1366–1372.
Crossref Google Scholar
40

Zhao Y, Yamashita T, Ishikawa M. Regulation of tumor invasion by HOXB13 gene overexpressed in human endometrial cancer. Oncol Rep. 2005;13:721–726.
Crossref Google Scholar
41

Miao J, Wang Z, Provencher H, et al. HOXB13 promotes ovarian cancer progression. Proc Natl Acad Sci USA. 2007;104:17093–17098.
Crossref Google Scholar
42

Lopez R, Garrido E, Pina P, et al. HOXB homeobox gene expression in cervical carcinoma. Int J Gynecol Cancer. 2006;16:329–335.
Crossref Google Scholar
43

Maeda K, Hamada J, Takahashi Y, et al. Altered expressions of HOX genes in human cutaneous malignant melanoma. Int J Cancer. 2005;114:436–441.
Crossref Google Scholar
44

Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;5:607–616.
Crossref Google Scholar
45

Kanai M, Hamada J, Takada M, et al. Aberrant expressions of HOX genes in colorectal and hepatocellular carcinomas. Oncol Rep. 2010;23:843–851.
Google Scholar
46

Cantile M, Scognamiglio G, La Sala L, et al. Aberrant expression of posterior HOX genes in well differentiated histotypes of thyroid cancers. Int J Mol Sci. 2013;14:21727–21740.
Crossref Google Scholar
47

Marra L, Cantile M, Scognamiglio G, et al. Deregulation of HOX B13 expression in urinary bladder cancer progression. Curr Med Chem. 2013;20:833–839.
Crossref Google Scholar
48

Mann RS, Lelli KM, Joshi R. Hox specificity unique roles for cofactors and collaborators. Curr Top Dev Biol. 2009;88:63–101.
Crossref Google Scholar
49

Chang CP, Shen WF, Rozenfeld S, Lawrence HJ, Largman C, Cleary ML. Pbx proteins display hexapeptide-dependent cooperative DNA binding with a subset of Hox proteins. Genes Dev. 1995;9:663–674.
Crossref Google Scholar
50

Burglin TR. The PBC domain contains a MEINOX domain: coevolution of Hox and TALE homeobox genes? Dev genes Evol. 1998;208:113–116.
Crossref Google Scholar
51

Moskow JJ, Bullrich F, Huebner K, Daar IO, Buchberg AM. Meis1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice. Mol Cell Biol. 1995;15:5434–5443.
Crossref Google Scholar
52

Moens CB, Selleri L. Hox cofactors in vertebrate development. Dev Biol. 2006;291:193–206.
Crossref Google Scholar
53

Mann RS, Affolter M. Hox proteins meet more partners. Curr Opin Genet Dev. 1998;8:423–429.
Crossref Google Scholar
54

Mukherjee K, Burglin TR. Comprehensive analysis of animal TALE homeobox genes: new conserved motifs and cases of accelerated evolution. J Mol Evol. 2007;65:137–153.
Crossref Google Scholar
55

Ariki R, Morikawa S, Mabuchi Y, et al. Homeodomain transcription factor Meis1 is a critical regulator of adult bone marrow hematopoiesis. PLoS One. 2014;9:e87646.
Crossref Google Scholar
56

Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 1998;17:3714–3725.
Crossref Google Scholar
57

Kumar AR, Li Q, Hudson WA, et al. A role for MEIS1 in MLL-fusion gene leukemia. Blood. 2009;113:1756–1758.
Crossref Google Scholar
58

Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev. 2007;21:2762–2774.
Crossref Google Scholar
59

Garcia-Cuellar MP, Steger J, Fuller E, Hetzner K, Slany RK. Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia. Haematologica. 2015;100:905–913.
Crossref Google Scholar
60

Calvo KR, Knoepfler PS, Sykes DB, Pasillas MP, Kamps MP. Meis1a suppresses differentiation by G-CSF and promotes proliferation by SCF: potential mechanisms of cooperativity with Hoxa9 in myeloid leukemia. Proc Natl Acad Sci USA. 2001;98:13120–13125.
Crossref Google Scholar
61

Mahmoud AI, Kocabas F, Muralidhar SA, et al. Meis1 regulates postnatal cardiomyocyte cell cycle arrest. Nature. 2013;497:249–253.
Crossref Google Scholar
62

Garcia-Borreguero D, Williams AM. An update on restless legs syndrome (Willis-Ekbom disease): clinical features, pathogenesis and treatment. Curr Opin Neurol. 2014;27:493–501.
Crossref Google Scholar
63

Jones TA, Flomen RH, Senger G, Nizetic D, Sheer D. The homeobox gene MEIS1 is amplified in IMR-32 and highly expressed in other neuroblastoma cell lines. Eur J Cancer. 2000;36:2368–2374.
Crossref Google Scholar
64

Geerts D, Revet I, Jorritsma G, Schilderink N, Versteeg R. MEIS homeobox genes in neuroblastoma. Cancer Lett. 2005;228:43–50.
Crossref Google Scholar
65

Geerts D, Schilderink N, Jorritsma G, Versteeg R. The role of the MEIS homeobox genes in neuroblastoma. Cancer Lett. 2003;197:87–92.
Crossref Google Scholar
66

Zha Y, Xia Y, Ding J, et al. MEIS2 is essential for neuroblastoma cell survival and proliferation by transcriptional control of M-phase progression. Cell Death Dis. 2014;5:e1417.
Crossref Google Scholar
67

Fernandez P, Carretero J, Medina PP, et al. Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations. Oncogene. 2004;23:5084–5091.
Crossref Google Scholar
68

Lasa A, Carnicer MJ, Aventin A, et al. MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias. Leukemia. 2004;18:1231–1237.
Crossref Google Scholar
69

Li W, Huang K, Guo H, Cui G. Meis1 regulates proliferation of non-small-cell lung cancer cells. J Thorac Dis. 2014;6:850–855.
Google Scholar
70

Sabates-Bellver J, Van der Flier LG, de Palo M, et al. Transcriptome profile of human colorectal adenomas. Mol Cancer Res. 2007;5:1263–1275.
Crossref Google Scholar
71

Crist RC, Roth JJ, Waldman SA, Buchberg AM. A conserved tissue-specific homeodomain-less isoform of MEIS1 is downregulated in colorectal cancer. PLoS One. 2011;6:e23665.
Crossref Google Scholar
72

Cui L, Li M, Feng F, et al. MEIS1 functions as a potential AR negative regulator. Exp Cell Res. 2014;328:58–68.
Crossref Google Scholar
73

Chen JL, Li J, Kiriluk KJ, et al. Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression. Clin Cancer Res. 2012;18:4291–4302.
Crossref Google Scholar
74

Jung C, Kim RS, Zhang HJ, Lee SJ, Jeng MH. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res. 2004;64:9185–9192.
Crossref Google Scholar
75

Ramberg H, Grytli HH, Nygard S, et al. PBX3 is a putative biomarker of aggressive prostate cancer. Int J Cancer. 2016;139:1810–1820.
Crossref Google Scholar
Genes & Diseases
Volume 4 Issue 2,
June 2017
Pages 75-87
DOI: 10.1016/j.gendis.2017.01.003
Cite this article:
Brechka H, Bhanvadia RR, VanOpstall C, et al. HOXB13 mutations and binding partners in prostate development and cancer: Function, clinical significance, and future directions. Genes & Diseases, 2017, 4(2): 75-87. https://doi.org/10.1016/j.gendis.2017.01.003

293

Views

3

Downloads

51

Crossref

N/A

Web of Science

50

Scopus

0

CSCD

Altmetrics
Received: 16 December 2016
Accepted: 31 January 2017
Published: 16 February 2017
© 2017, Chongqing Medical University.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return